Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...